Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a report issued on Wednesday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners initiated coverage on Lipocine in a report on Tuesday, September 24th. They issued a “buy” rating and a $10.00 target price for the company.

Lipocine Trading Up 4.1 %

NASDAQ LPCN opened at $5.06 on Wednesday. Lipocine has a 1-year low of $2.82 and a 1-year high of $11.79. The firm’s fifty day simple moving average is $5.04 and its 200-day simple moving average is $5.24. The company has a market capitalization of $27.06 million, a PE ratio of -6.66 and a beta of 1.24.

Lipocine (NASDAQ:LPCN) last released its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) EPS for the quarter. As a group, analysts predict that Lipocine will post -0.78 EPS for the current year.

Institutional Investors Weigh In On Lipocine

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP bought a new stake in shares of Lipocine Inc. (NASDAQ:LPCN) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine at the end of the most recent reporting period. 9.11% of the stock is owned by institutional investors and hedge funds.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.